ITCI - Intra-Cellular Therapies, Inc.

QQQ $ 482.88 $ 2.24 (0.47 %)

DIA $ 408.91 $ 0.43 (0.11 %)

SPY $ 560.81 $ 1.92 (0.34 %)

TLT $ 98.72 $ 0.06 (0.06 %)

GLD $ 232.16 $ -0.31 (-0.13 %)

Previous Close

$ 75.69

Open

$ 77.28

Bid

$ 75.62 x 100

Ask

-- x --

Day's Range

$ 74.94 - $ 78.12

52 Week Range

$ 45.50 - $ 84.89

Volume

755,151

Average Volume

Market Cap

7.85B

Beta (5Y Monthly)

$ 0.86

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-07-2024	06-30-2024	10-Q
2	05-07-2024	03-31-2024	10-Q
3	02-22-2024	12-31-2023	10-K
4	11-02-2023	09-30-2023	10-Q
5	08-03-2023	06-30-2023	10-Q
6	05-04-2023	03-31-2023	10-Q
7	03-01-2023	12-31-2022	10-K
8	11-03-2022	09-30-2022	10-Q
9	08-09-2022	06-30-2022	10-Q
10	05-10-2022	03-31-2022	10-Q
11	03-01-2022	12-31-2021	10-K
12	11-09-2021	09-30-2021	10-Q
13	08-09-2021	06-30-2021	10-Q
14	05-10-2021	03-31-2021	10-Q
15	02-25-2021	12-31-2020	10-K
16	11-09-2020	09-30-2020	10-Q
17	08-10-2020	06-30-2020	10-Q
18	05-07-2020	03-31-2020	10-Q
19	03-02-2020	12-31-2019	10-K
20	11-05-2019	09-30-2019	10-Q
21	08-07-2019	06-30-2019	10-Q
22	05-08-2019	03-31-2019	10-Q
23	02-27-2019	12-31-2018	10-K
24	11-07-2018	09-30-2018	10-Q
25	08-02-2018	06-30-2018	10-Q
26	05-03-2018	03-31-2018	10-Q
27	03-01-2018	12-31-2017	10-K
28	11-08-2017	09-30-2017	10-Q
29	08-09-2017	06-30-2017	10-Q
30	05-10-2017	03-31-2017	10-Q
31	03-01-2017	12-31-2016	10-K
32	11-09-2016	09-30-2016	10-Q
33	08-04-2016	06-30-2016	10-Q
34	04-28-2016	03-31-2016	10-Q
35	04-28-2016	03-31-2016	10-Q
36	02-25-2016	12-31-2015	10-K
37	11-05-2015	09-30-2015	10-Q
38	08-05-2015	06-30-2015	10-Q
39	04-30-2015	03-31-2015	10-Q
40	03-12-2015	12-31-2014	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

JP Morgan Maintains Overweight on Intra-Ce...
08/21/2024 14:13:41

JP Morgan analyst Jessica Fye maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Overweight and raises the price target...

RBC Capital Maintains Outperform on Intra-...
08/08/2024 19:54:16

RBC Capital analyst Brian Abrahams maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Outperform and lowers the price t...

Cantor Fitzgerald Maintains Overweight on ...
08/08/2024 15:23:45

Cantor Fitzgerald analyst Charles Duncan maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Overweight and raises the p...

UBS Maintains Neutral on Intra-Cellular Th...
08/08/2024 14:22:04

UBS analyst Ashwani Verma maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Neutral and lowers the price target from $...

Goldman Sachs Maintains Neutral on Intra-C...
08/08/2024 12:07:43

Goldman Sachs analyst Corinne Jenkins maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Neutral and lowers the price t...

Needham Reiterates Buy on Intra-Cellular T...
08/08/2024 11:35:06

Needham analyst Ami Fadia reiterates Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and maintains $100 price target.

Deep Dive Into Intra-Cellular Therapies St...
08/07/2024 13:00:50

Needham Reiterates Buy on Intra-Cellular T...
08/07/2024 12:15:38

Needham analyst Ami Fadia reiterates Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and maintains $100 price target.

Intra-Cellular Therapies Announced That Sa...
08/07/2024 11:43:13

Intra-Cellular Therapies Sees 2024 CAPLYTA...
08/07/2024 11:32:09

Intra-Cellular Therapies Q2 2024 GAAP EPS ...
08/07/2024 11:31:41

Intra-Cellular Therapies (NASDAQ:ITCI) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate...

nvidia-to-rally-around-19-here-are-10-top-analyst-forecasts-for-monday

NVIDIA To Rally Around 19%? Here Are 10 To...
07/22/2024 13:17:58

A Closer Look at 11 Analyst Recommendation...
07/22/2024 13:00:55

Needham Maintains Buy on Intra-Cellular Th...
07/22/2024 09:29:14

Needham analyst Ami Fadia maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and raises the price target from $94 t...

UBS Downgrades Intra-Cellular Therapies to...
06/25/2024 16:16:36

UBS analyst Ashwani Verma downgrades Intra-Cellular Therapies (NASDAQ:ITCI) from Buy to Neutral and lowers the price target ...

RBC Capital Reiterates Outperform on Intra...
06/25/2024 14:10:14

RBC Capital analyst Brian Abrahams reiterates Intra-Cellular Therapies (NASDAQ:ITCI) with a Outperform and maintains $103 pr...

chinas-bilibili-and-ollies-bargain-outlet-were-among-10-mid-cap-stocks-with-biggest-gains-in-the-last-week-june-16-june-22-2024-are-they-in-your-portfolio

China's Bilibili And Ollie's Bargain Outle...
06/23/2024 22:21:43

Top performing mid-cap stocks last week: BILI (+23%), IBRX (+22%), SSL (+20%), OLLI (+15%), ITCI (+13%), AMKR (+12%), IRTC (+11...

Mizuho Maintains Buy on Intra-Cellular The...
06/21/2024 11:30:18

Mizuho analyst Graig Suvannavejh maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and raises the price target fro...

Canaccord Genuity Maintains Buy on Intra-C...
06/20/2024 16:32:49

Canaccord Genuity analyst Sumant Kulkarni maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and raises the price t...

Needham Maintains Buy on Intra-Cellular Th...
06/18/2024 16:44:52

Needham analyst Ami Fadia maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and raises the price target from $90 t...